1. Engineered Biomimetic Nanovesicles Synergistically Remodel Folate-Nucleotide and γ-Aminobutyric Acid Metabolism to Overcome Sunitinib-Resistant Renal Cell Carcinoma.
- Author
-
Lv M, Liu B, Duan Y, Lin J, Dai L, Li Y, Yu J, Liao J, Zhang J, and Duan Y
- Subjects
- Humans, Animals, Mice, Nanoparticles chemistry, Nucleotides chemistry, Nucleotides metabolism, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Biomimetic Materials chemistry, Biomimetic Materials pharmacology, Biomimetic Materials metabolism, Cell Line, Tumor, Tumor Microenvironment drug effects, Cell Proliferation drug effects, Epithelial-Mesenchymal Transition drug effects, Aminohydrolases, Methylenetetrahydrofolate Dehydrogenase (NADP), Oxides, Multifunctional Enzymes, Carcinoma, Renal Cell drug therapy, Carcinoma, Renal Cell metabolism, Carcinoma, Renal Cell pathology, Drug Resistance, Neoplasm drug effects, Kidney Neoplasms drug therapy, Kidney Neoplasms metabolism, Kidney Neoplasms pathology, Folic Acid chemistry, Folic Acid metabolism, Sunitinib pharmacology, Sunitinib chemistry, gamma-Aminobutyric Acid metabolism, gamma-Aminobutyric Acid chemistry, Manganese Compounds chemistry, Manganese Compounds pharmacology
- Abstract
Reprogramming of cellular metabolism in tumors promoted the epithelial-mesenchymal transition (EMT) process and established immune-suppressive tumor microenvironments (iTME), leading to drug resistance and tumor progression. Therefore, remodeling the cellular metabolism of tumor cells was a promising strategy to overcome drug-resistant tumors. Herein, CD276 and MTHFD2 were identified as a specific marker and a therapeutic target, respectively, for targeting sunitinib-resistant clear cell renal cell carcinoma (ccRCC) and its cancer stem cell (CSC) population. The blockade of MTHFD2 was confirmed to overcome drug resistance via remodeling of folate-nucleotide metabolism. Moreover, the manganese dioxide nanoparticle was proven here by a high-throughput metabolome to be capable of remodeling γ-aminobutyric acid (GABA) metabolism in tumor cells to reconstruct the iTME. Based on these findings, engineered CD276-CD133 dual-targeting biomimetic nanovesicle EMφ-siMTHFD2-MnO
2 @Suni was designed to overcome drug resistance and terminate tumor progression of ccRCC. Using ccRCC-bearing immune-humanized NPG model mice, EMφ-siMTHFD2-MnO2 @Suni was observed to remodel folate-nucleotide and GABA metabolism to deactivate the EMT process and reconstruct the iTME thereby overcoming the drug resistance. In the incomplete-tumor-resection recurrence model and metastasis model, EMφ-siMTHFD2-MnO2 @Suni reduced recurrence and metastasis in vivo. This work thus provided an innovative approach that held great potential in the treatment of drug-resistant ccRCC by remodeling cellular metabolism.- Published
- 2024
- Full Text
- View/download PDF